Ketek Additional Safety Data May Be Required Before Approval
Executive Summary
Aventis Ketek (telithromycin) may require more safety information before the drug is approved for any indication, including community-acquired pneumonia, FDA's Anti-Infective Drugs Advisory Committee indicated.
You may also be interested in...
Ketek 24,000-Patient Trial Should Be New “Benchmark” For Antibiotics
Aventis' 24,000-patient "usual care" study for Ketek should be the benchmark for investigational antibiotic safety trials, FDA Anti-Infective Drugs Advisory Committee voting consultant William Lee, MD, University of Texas Southwestern Medical School, said Jan. 8
Ketek 24,000-Patient Trial Should Be New “Benchmark” For Antibiotics
Aventis' 24,000-patient "usual care" study for Ketek should be the benchmark for investigational antibiotic safety trials, FDA Anti-Infective Drugs Advisory Committee voting consultant William Lee, MD, University of Texas Southwestern Medical School, said Jan. 8
QT Prolongation Alone Does Not Assess Arrhythmic Potential - FDA's Lipicky
Cardiac QT interval prolongation alone is not a sufficient measure of a drug's potential to cause arrhythmic disturbances, FDA Division of Cardio-Renal Drug Products Director Raymond Lipicky, MD, suggested.